Trial · NCT03301038
Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria
NCT03301038, Phase 2, Recruiting, Children's Hospital of Philadelphia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria. Trials, record NCT03301038. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03301038
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria
- NCT number
- NCT03301038
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Children's Hospital of Philadelphia
- Conditions
- Idiopathic Infantile Hypercalcaemia - Severe Form, Genetic Disease, Hypercalcemia, Idiopathic, of Infancy, Hypercalciuric Hypercalcemia, Idiopathic Infantile Hypercalcemia - Mild Form, Hypercalciuria
- Interventions
- Rifampin
- First posted
- 2017-10-04
- Last updated
- 2026-10-13
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Serum albumin-adjusted calcium | up to 32 weeks | Measured at baseline and every 4 weeks |
| Primary | Serum parathyroid hormone | up to 32 weeks | Measured at baseline and every 4 weeks |
| Primary | Urinary calcium excretion | up to 32 weeks | Measured at baseline and every 4 weeks |
| Secondary | Intestinal calcium absorption | baseline, 8, 16, 24 and 32 weeks post-dose | Measured using stable calcium isotopes five times during the study |
| Secondary | Nephrocalcinosis | Baseline and week 32 | Renal ultrasound performed before and after treatment |
| Secondary | Rifampin pharmacokinetics | 8, 16 and 24 weeks post-dose | Measured three times during the study |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01DK112955 | Repurposing rifampin to reduce elevated levels of blood and urine calcium in patients with inactivating mutations of CYP24A1 | LEVINE, MICHAEL A.; WEBER, DAVID R | CHILDREN'S HOSP OF PHILADELPHIA | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2017 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03301038
GET https://conductscience.org/api/trials/v1/NCT03301038/registered